BiotechTube
LightLine Medical

LightLine Medical

San Francisco, United States· Est.
lightlinemedical.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

LightLine Medical is a private, pre-revenue medical device startup founded in 2019, based in San Francisco. The company has developed a patented photodisinfection platform that uses visible light to disinfect the interior and exterior of translucent catheters, aiming to prevent deadly and costly device-associated infections. Its initial focus is on peritoneal dialysis catheters, Foley catheters, endotracheal tubes, and central/PICC lines, addressing a multi-billion dollar problem of hospital-acquired infections. The technology represents a non-antibiotic, non-UV approach to combating drug-resistant microbes.

Infectious DiseaseNephrologyUrologyCritical CarePulmonology

Technology Platform

Patented PhotoDisinfection System using visible light (not UV) to disinfect both interior and exterior surfaces of translucent catheters and tubes, killing microbes including antibiotic-resistant pathogens.

Opportunities

The massive and costly burden of hospital-acquired infections ($50B annually in the U.S.) creates a strong demand for effective prevention technologies.
The shift to value-based care and penalties for HAIs provides a powerful economic incentive for hospitals to adopt solutions like LightLine's.
The platform's applicability across multiple high-incidence catheter types allows for a diversified market approach.

Risk Factors

The technology is unproven in large-scale clinical trials and must navigate a stringent FDA regulatory pathway.
As a pre-revenue startup, the company is dependent on external funding to reach commercialization.
It faces competition from existing infection prevention methods and must convince healthcare systems to adopt a new clinical protocol.

Competitive Landscape

LightLine competes in the catheter infection prevention market against antimicrobial-coated catheters (e.g., from Bard/BD, Teleflex), antibiotic lock solutions, chlorhexidine-based dressings, and other disinfection technologies. Its key differentiator is the use of visible light for a non-chemical, non-antibiotic mechanism that targets both lumen and exterior surfaces, potentially offering a broader spectrum of action against resistant pathogens.

More companies in Regenerative Medicine →More companies in United States →